ARS Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
81.9%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$132.3Mnext fiscal year
FY EPS (est.)
-$1.84next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
U.S. neffy Net Product Revenue Quarterly17.5M
Total Revenue Quarterly22.7M
Cash, Cash Equivalents, and Short-Term Investments Quarterly201M
U.S. Patients Using neffy Quarterly120K
Active Prescribers Quarterly28K
Watch Items
- Commercial Formulary Inclusion and Payer Coverage DecisionsTrigger: Target effective date of July 1, 2026Action: Monitor official announcements regarding unrestricted formulary access and subsequent gross-to-net retention impact.
- Phase 2b Chronic Spontaneous Urticaria (CSU) Trial Data ReadoutTrigger: Interim data readout expected in Q4 2026Action: Evaluate efficacy and safety profile to assess potential Phase 3 trial initiation in 2027 and addressable market expansion.
- Cash Runway and Cash-Flow Break-Even TimelineTrigger: Anticipated cash-flow break-even by mid-2027Action: Track quarterly cash burn rate and SG&A optimization to ensure current cash reserves of $201 million are sufficient without dilutive financing.
Research as of 19 Jun 2026